Gus Gazzard

Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension.

Selective laser trabeculoplasty is a safe treatment for OAG and OHT, providing better long-term disease control than initial drop therapy, with reduced need for incisional glaucoma and cataract surgery over 6 years.

Primary Selective Laser Trabeculoplasty for Open-Angle Glaucoma and Ocular Hypertension: Clinical Outcomes, Predictors of Success, and Safety from the Laser in Glaucoma and Ocular Hypertension Trial.

Primary SLT achieved comparable early absolute IOP-lowering in OHT versus OAG eyes.

Long-term Outcomes from the HORIZON Randomized Trial for a Schlemm's Canal Microstent in Combination Cataract and Glaucoma Surgery.

The addition of a Schlemm's canal microstent in conjunction with CS was safe, resulted in lowered IOP and medication use, and reduced the need for postoperative incisional glaucoma filtration surgery compared with CS after 5 years.

Minimally Invasive Glaucoma Surgical Techniques for Open-Angle Glaucoma: An Overview of Cochrane Systematic Reviews and Network Meta-analysis.

Based on data synthesized in Cochrane reviews, some MIGS may afford patients with glaucoma greater drop-free disease control than cataract surgery alone.

Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology.

The LiGHT Trial is a multicentre, pragmatic, randomised clinical trial that will provide valuable data on the relative HRQL, clinical effectiveness and cost-effectiveness of SLT and topical IOP-lowering medication.

Three-Year Findings of the HORIZON Trial: A Schlemm Canal Microstent for Pressure Reduction in Primary Open-Angle Glaucoma and Cataract.

Combined CS and microstent placement for mild to moderate POAG is safe, more effective in lowering IOP with fewer medications, and less likely to result in further incisional glaucoma filtration surgery than CS alone at…

Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT).

A slightly larger proportion of ocular hypertensive and glaucoma patients treated first with medical therapy underwent rapid VF progression compared with those treated first with SLT.

Efficacy of Repeat Selective Laser Trabeculoplasty in Medication-Naive Open-Angle Glaucoma and Ocular Hypertension during the LiGHT Trial.

These exploratory analyses demonstrate that repeat SLT can maintain IOP at or below target IOP in medication-naive OAG and OHT eyes requiring retreatment with at least an equivalent duration of effect to initial laser.

Five-Year Visual Field Outcomes of the HORIZON Trial.

CS-HMS has a significant effect on VF preservation in glaucoma patients compared with CS alone, reducing the proportion of fast progressors.

The Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics.

The LiGHT trial is the first RCT to compare the two treatment options in a real-world setting. The baseline characteristics of the LiGHT cohort compare well with other landmark glaucoma studies.

Low-energy Selective Laser Trabeculoplasty Repeated Annually: Rationale for the COAST Trial.

A new study--Clarifying the Optimal Application of SLT Therapy --has been initiated to explore this preliminary finding in a pair of consecutive randomized trials.

A Scoping Review of Quality of Life Questionnaires in Glaucoma Patients.

Wide variability among questionnaires used to determine vision related QoL in glaucoma and in the responses elicited was identified.

The Impact of Baseline Intraocular Pressure on Initial Treatment Response in the LiGHT Trial: Selective Laser Trabeculoplasty versus Medication.

We confirm previous reports of greater IOP lowering with higher baseline IOP for both SLT and PGA drops.

Patients With Normal Tension Glaucoma Have Relative Sparing of the Relative Afferent Pupillary Defect Compared to Those With Open Angle Glaucoma and Elevated Intraocular Pressure.

Glaucoma patients with NTG have a lesser RAPD for a given level of intereye difference of HVF MD, compared to patients with high IOPs.

Laser in Glaucoma and Ocular Hypertension Trial (LIGHT) in China - A Randomized Controlled Trial: Design and Baseline Characteristics.

Compared with participants in the LiGHT UK trial, participants in this trial were younger, more myopic and had more severe visual field defects.

Energy Dose-Response in Selective Laser Trabeculoplasty: A Review.

The optimal energy level of SLT needed for IOP reduction has not yet been definitively established, with all reported pulse energies resulting in similar IOP reduction.

Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement.

We propose a consensus-based series of outcomes and assessment methods to be used in clinical trials assessing adverse effects of antiglaucomatous eye drops.

Design and Conduct of Randomized Clinical Trials Evaluating Surgical Innovations in Ophthalmology: A Systematic Review.

Important aspects of the study design such as the surgical learning curve, surgeon's previous experience, quality assurance, and trial registration details were often missing in novel ophthalmic surgical procedures.

Selective Laser Trabeculoplasty After Medical Treatment for Glaucoma or Ocular Hypertension.

This secondary analysis of a randomized clinical trial found that secondary SLT was associated with a reduction in the medication load for stable, medically treated eyes.

Responsiveness to Selective Laser Trabeculoplasty in Open-Angle Glaucoma and Ocular Hypertension.

These post hoc analyses showed that most cases of OAG and OHT were highly responsive to SLT and support the consideration of repeat SLT regardless of initial response, while individuals who are nonresponsive to this…

Randomized Noninferiority Trial of Direct Selective Laser Trabeculoplasty in Open-Angle Glaucoma and Ocular Hypertension: GLAUrious Study.

The 6-month primary end point did not achieve statistical noninferiority compared with conventional SLT.

A Proposal for the Use of a Fixed Low-Energy Selective Laser Trabeculoplasty for Open Angle Glaucoma.

Despite these variations in laser parameters, SLT consistently reduces IOP with a low complication rate.

Rethinking Prophylactic Laser Peripheral Iridotomy in Primary Angle-Closure Suspects: A Review.

The ZAP-Trial and ANA-LIS clearly represent the best available data on PACS management, additional parameters however may need to be considered when physicians face patients in clinic.

Re: Gedde et al: Special Commentary: Reporting clinical endpoints in studies of minimally invasive glaucoma surgery (Ophthalmology. 2025;132:141-153).

Disease Progression, not Intraocular Pressure, Should Guide Escalation of Treatment in Glaucoma.

Missed Opportunities in Preventing Acute Angle Closure-Needlessly Blind?

Six-Year Rate of Visual Field Progression in the Laser in Glaucoma and Ocular Hypertension Trial.

First-line SLT was more effective than drops at preserving VF.

The adverse effects of oral niacin/nicotinamide - an overview of reviews.

Standardised dosing, outcome measures and adverse effects should be utilised in further research and a surveillance system for reporting adverse effects.

Impact of Different Intraocular Pressure and Medication Endpoint Criteria on Success Rates in Subconjunctival Minimally Invasive Glaucoma Surgery.

Using different IOP and medication criteria to define success can have a significant influence on the apparent risk of failure, particularly at the 21 mm Hg threshold and when incorporating a minimum 20% IOP reduction from baseline.

Trabeculectomy Augmented With Anti-VEGF Improves Surgical Outcomes in Glaucoma: A Systematic Review and Meta-Analysis.

Anti-VEGF agents improve trabeculectomy outcomes when used with Mitomycin-C, enhancing complete success rates and reducing medication needs.

Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records.

We performed an external validation of the OHTS-EGPS model in a large English population.

Managing primary open-angle glaucoma in the setting of suboptimal surgical outcomes in the fellow eye.

A 62-year-old woman with mild myopia presented to her local optometrist for a routine examination and was found to have intraocular pressure (IOP) of 30 mm Hg in both eyes and cupped nerves.

Assessing the Fragility of Statistically Significant Outcomes in Randomised Controlled Trials of Minimally Invasive Glaucoma Surgery (MIGS).

Statistically significant outcomes in RCTs of MIGS exhibit variable statistical robustness when assessed using fragility metrics, often due to small numbers of events.

Adherence of glaucoma intervention studies to World Glaucoma Association guidelines.

Current literature shows poor adherence to WGA guidelines across both traditional and newer glaucoma surgeries, reflecting inadequate reporting and outdated recommendations.

Fields from home: device-independent online perimetry with Melbourne Rapid Fields.

Home-perimetry produced more variable results than in-clinic testing, but the increased testing frequency enabled the potential earlier detection of progression compared to standard in-clinic testing.

Open Angle Glaucoma Treatment Preferences of Glaucoma Specialists in the United States.

The majority of US glaucoma specialists report a preference for SLT over medication for open angle glaucoma treatment, demonstrating that acceptance of SLT has increased over the past several years, especially for treatment-naïve patients.

Registry-based randomised controlled trials in glaucoma: the time is right?

Comparison of baseline clinical characteristics and patterns of visual field defects between high-tension and normal-tension glaucoma.

In the LiGHT China trial, NTG and HTG showed similar visual field defects severity at enrolment.

Association of Systemic Calcium Channel Blocker Use with Visual Field Progression in a Large Real-World Cohort from Glaucoma Clinics.

Calcium channel blocker use was statistically significantly associated with a slower rate of VF deterioration after multivariable adjustment.

Selective Laser Trabeculoplasty and the Evolving Glaucoma Paradigm.

We will also describe our conversations with patients about SLT, with the goal of facilitating readers' integration of primary SLT into their clinical practices.

Design and Baseline Characteristics of Participants in the Clarifying the Optimal Application of Selective Laser Trabeculoplasty (SLT) Therapy (COAST) Trial 1.

The COAST trial compares standard versus low-energy SLT for new ocular hypertension/glaucoma. Its robust design and representative patient population will clarify optimal SLT use for long-term glaucoma management, potentially reducing reliance on other therapies.

Optometrist-delivered selective laser trabeculoplasty in the HES - a training protocol and early service evaluation.

The training programme is based on medical education principles, is informed by previous qualitative research into the role of ophthalmic practitioners in the delivery of laser treatments and is expected to have multidisciplinary benefits for ophthalmic healthcare.